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purposes. Representatives of that 
company pointed out that their 
cells are not guaranteed to be free 
from bacterial and viral infections 
to the standards that would be 
required for medical use.
The BBC program also alleges 
that Advanced Cell Therapeutics 
tried to obscure the origin of the 
cells by storing them in the UK, 
using the services of companies 
that were led to believe that these 
cells were for research purposes 
only. Following the revelations, 
however, this route is likely to be 
blocked, as the medical use of 
such cells would be illegal in the 
UK and even their handling and 
storage for other purposes than 
research might violate the Human 
Tissues Act drawn up in response 
to the organ retention scandals 
(Curr. Biol. 14, R254).
“It is important not to 
judge the potential future 
benefits of stem cell  
biology from the actions 
of those who have shown 
such flagrant disregard for 
the lives of their patients.”
In a global market, however, 
people will continue to find ways 
of offering dubious medicine, 
using internet marketing and 
legal loopholes in countries 
around the world. Advanced Cell 
Therapeutics, for example, has 
been carrying out its treatments 
in Ireland until recently, and, when 
the authorities stepped in, there 
were press reports suggesting 
that the company offered the 
treatment on board a ferry, in 
international waters instead. 
Similarly, the company Medra, 
based in Malibu, California, offers 
injections of “human fetal stem 
cells” to treat diseases ranging 
from Alzheimer’s through to 
ulcerative colitis, to be carried 
out in the Dominican Republic. 
The company’s fact sheet guards 
tactful silence on the origin of 
these cells.
Fairchild concludes: “While 
the practice of companies such 
as Advanced Cell Therapeutics 
and Medra is truly shocking, it 
is important not to judge the 
potential future benefits of stem 
cell biology from the actions of 
those who have shown such 
flagrant disregard for the lives of 
their patients.”
So, is there any real hope for 
patients with chronic disease to 
benefit from stem cell therapies 
in the near future? Most 
treatment options that are being 
investigated in the lab right now 
will need many years before 
they might reach the patient. 
However, there is some more 
promising, if cautious, news on 
stem cells. The company Geron, 
based at Menlo Park, California, 
is testing a range of stem 
cell treatments in preclinical 
trials, and is expecting to 
start the first Phase I clinical 
trial early next year, which will 
most likely involve a possible 
treatment for acute spinal cord 
injury. 
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benefit of human stem cells are 
not the only problem emerging 
from rapid developments in 
biology. The use of DNA analyses 
is proving a tempting target for 
many companies. There is no 
doubt that the sequencing of the 
human genome was a spectacular 
achievement, announced by 
President Clinton in 2000. But 
many commentators then glossed 
over the difficulties that lay ahead 
in transferring that information 
into useful medical advances.
So far, despite an explosion of 
research into how our genetic 
make-up puts us at risk of disease 
and affects our reaction to drugs 
or environmental toxins, there 
have been few concrete changes 
in the way doctors administer 
healthcare.
But companies looking to cash 
in by analysing DNA don’t have 
the same caution. Do your genes 
make you metabolise coffee 
and alcohol more quickly than 
most people? Are you prone to 
osteoporosis and Alzheimer’s 
in old age? Do you have the 
potential for sporting greatness? 
Plenty are willing to answer, if you 
are prepared to pay.
A US study of some companies 
offering DNA analysis has raised 
concerns. Nigel Williams reports.
Worries over 
consumer gene 
testsThere’s just one problem: the 
genetic testing services available 
at present can’t give you that 
power — though they might aspire 
to, or insist they can.
Their fallibility was uncovered 
by a US Government 
Accountability Office investigation 
this summer. Over nearly a 
year, the GAO’s investigators 
anonymously approached four 
online companies for testing 
services. They posed as 14 
different would-be consumers 
with a variety of profiles such as 
age, weight, smoking and exercise 
habits. In reality, they sent 
samples of DNA provided from 
just two people — a 48-year-old 
man and a nine-month-old girl.
The GAO’s report shows that 
the companies, which charged 
between $89 and $395 for the 
tests, provided inconsistent 
results and offered vague and 
misleading advice to their 
supposed clients. One offered 
supposedly tailored nutritional 
supplements costing up to $1,200 
per year; they turned out to be 
run-of-the-mill multivitamin tablets 
that could be bought on the high 
street for $35 a year.
The companies to whom the 
samples were sent were: Suracell 
from Montclair, Sciona Inc. of 
Boulder, Colorado, Genaissance 
Pharmaceuticals of Newton, 
Massachusetts, and Genox and 
Genelex Corp. of Seattle — and 
all deny any impropriety.
The GAO said: “Although 
some types of diseases, such as 
cystic fibrosis, can be definitively 
diagnosed by looking at certain 
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spoke with said that the medical 
predictions in the test results can 
not be medically proven at this 
time.”
“Even if the predictions 
could be medically proven, the 
way the results are presented 
renders them meaningless. 
For example, many people 
‘may’ be at ‘increased risk’ for 
developing heart disease, so 
such an ambiguous statement 
could relate to any human that 
submitted DNA.”
The GAO also said that 
unproven predictions made by 
companies “may needlessly 
alarm consumers into thinking 
that they have an illness or 
that they need to buy costly 
supplements in order to prevent 
an illness. Perhaps even more 
troubling, the test results may 
falsely assure consumers that 
they are healthy when this may 
not be the case.”
The report’s authors said: 
“Despite the implication that 
these predictions are based on the DNA submitted, none […] 
contained scientific support to 
assist the consumer in evaluating 
their credibility.” Genetics experts 
told the GAO that none of the 
sites’ predictions about links 
between genes and health — with 
osteoporosis, heart disease, 
diabetes, cancer, or cholesterol 
and toxin metabolism — could be 
medically proved at present.
Furthermore one nutritionist 
flagged the level of vitamin 
B6 in some recommended 
products as ‘disturbing’, while 
another felt there were high 
levels of vitamin A and that one 
site’s supplements contained 
excessive iron, which could 
remain in the blood and become 
toxic.
One of the companies tested 
by the GAO has since ceased 
offering services in the UK 
following a negative review by 
the Human Genetics Commission 
in 2003. But even if these 
developments have provided a 
hiccup in company approach 
to genetic data, DNA is still considered to offer a new front 
in medicine: pharmacogenetics. 
This aims to understand how 
genetic make-up affects the 
reaction to specific drugs.
With it, doctors could match 
treatments to patients to speed 
up cures and minimalise negative 
reactions to medication. Old 
drugs abandoned because of 
adverse effects in some test 
patients could be revived, if there 
is a genetic base to the response 
that would not affect other 
patients.
But one concern with the cost 
of developing new medicines is 
that if genetic studies indicated 
that only a proportion of 
potential patients were likely 
to benefit from a drug, then its 
development may seem less 
attractive.
But the prospect is still 
promising. The anti-cancer drug 
newly in use, herceptin, works well 
only against tumours expressing 
particular genes. It is likely that 
other successful therapies will 
follow this line.Bar codes: Researchers and regulators are concerned about some claims made for the interpretation of human genetic data. (Photo: 
Philippe Plailly/Science Photo Library.)
